Your session is about to expire
← Back to Search
Gamma-Delta T Cell Therapy for Glioblastoma (DRI Trial)
DRI Trial Summary
This trial is testing an experimental cell therapy to see if it is safe to give to patients with newly diagnosed glioblastoma multiforme, in combination with the standard treatment of temozolomide.
DRI Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowDRI Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.DRI Trial Design
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Media Library
- I do not have any severe illnesses or mental health issues that would prevent me from following the study's requirements.I needed more steroids recently before getting a specific cell therapy.I have had encephalitis, multiple sclerosis, or another brain infection.I cannot have a device placed in my brain due to medical reasons.My organ and bone marrow functions are within normal ranges.I have never had an organ or bone marrow transplant.My MRI suggests I might have a serious brain tumor.I've finished initial treatment for brain cancer and am ready for ongoing therapy.I am 18 years old or older.You are expected to live for at least 12 more weeks.I am able to care for myself and perform normal activities.You are allergic or very sensitive to certain medications.I have not received treatment for GBM before joining Part A of the study.Women who could become pregnant must use approved birth control methods.My diagnosis of glioblastoma has been confirmed by lab tests.
- Group 1: DRI cell therapy
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Does this clinical trial have any open positions for participants?
"Affirmative. Clinicaltrials.gov shows that this clinical trial is actively recruiting, having posted on February 11th 2020 and lastly updated on February 1st 2022. A total of 12 patients are required from a single medical center for partaking in the study."
What is the maximum enrolment rate for this trial?
"Affirmative. Data hosted on clinicaltrials.gov confirms that this medical study, which was initially published on February 11th 2020, is actively recruiting participants for its 12-person cohort from a single location."
To what degree can DRI cell therapy be hazardous to human health?
"The safety of the DRI cell therapy is rated as a 1 based on its Phase 1 clinical trial status. This implies that there is little to no evidence regarding efficacy or security."
Share this study with friends
Copy Link
Messenger